You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Revlimid

Showing 1 - 25 of 598
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma Trial (RP followed by MPR)

Active, not recruiting
  • Multiple Myeloma
  • RP followed by MPR
  • (no location specified)
Mar 24, 2022

Multiple Myeloma Trial (Dara-VRd intensification, Dara-R maintenance, AHCT intensification, Dara-R maintenance, AHCT

Not yet recruiting
  • Multiple Myeloma
  • Dara-VRd intensification, Dara-R maintenance
  • +4 more
  • (no location specified)
Dec 13, 2022

Analyze Occurrence of Transformation From Myelodysplastic

Completed
  • Myelodysplastic Syndromes
  • Leukemia, Myeloid, Acute
    • Kobe, Hyogo, Japan
      Shinko Hospital
    Jun 13, 2022

    Multiple Myeloma Trial in Charlotte (Elotuzumab)

    Active, not recruiting
    Has Results
    • Multiple Myeloma
    • Charlotte, North Carolina
      Levine Cancer Institute
    Jan 24, 2023

    Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the National Cancer Institute (NCI) (Venetoclax, Ibrutinib, Prednisone)

    Recruiting
    • Lymphoma
    • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Aug 20, 2022

    Multiple Myeloma Trial in New York (carfilzomib, Dexamethasone, Clarithromycin)

    Active, not recruiting
    Has Results
    • Multiple Myeloma
    • New York, New York
      Weill Cornell Medical College
    Apr 10, 2022

    Chronic Lymphocytic Leukemia(CLL), Small Lymphocytic Lymphoma Trial in Hackensack (Revlimid, Azacitidine)

    Terminated
    Has Results
    • Chronic Lymphocytic Leukemia(CLL)
    • Small Lymphocytic Lymphoma
    • Hackensack, New Jersey
      Hackensack University Medical Center
    Jun 24, 2022

    Myelodysplastic Syndrome Trial in New York (Revlimid (Lenalidomide))

    Active, not recruiting
    Has Results
    • Myelodysplastic Syndrome
    • Revlimid (Lenalidomide)
    • New York, New York
      Columbia University Medical Center
    Jan 12, 2022

    Revlimid® Capsules General Drug Use-results Surveillance

    Recruiting
    • Lymphoma Nonhodgkin
      • Japan, Japan
        Local Institution
      Jun 22, 2022

      Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the NCI (obinutuzumab, prednisone, Revlimid)

      Recruiting
      • Lymphoma
      • +3 more
      • obinutuzumab
      • +5 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jul 6, 2022

      Non-Hodgkin Lymphoma Trial in Cologne (Tafasitamab, Lenalidomide, Rituximab)

      Not yet recruiting
      • Non-Hodgkin Lymphoma
      • Cologne, Germany
        University of Cologne
      Oct 14, 2022

      Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Huntsville, Bethesda (Ublituximab,

      Terminated
      • Non-Hodgkins Lymphoma
      • +6 more
      • Huntsville, Alabama
      • +1 more
      May 5, 2022

      Chronic Lymphocytic Leukemia, CLL Trial in La Jolla (Revlimid, Rituximab)

      Active, not recruiting
      Has Results
      • Chronic Lymphocytic Leukemia
      • CLL
      • La Jolla, California
        University of California, San Diego
      Sep 2, 2021

      Multiple Myeloma Trial in Aurora, New York (Clarithromycin, Lenalidomide, Dexamethasone)

      Active, not recruiting
      • Multiple Myeloma
      • Aurora, Colorado
      • +1 more
      Feb 1, 2022

      Primary Diffuse Large B-cell Lymphoma of the CNS (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS Trial

      Suspended
      • Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
      • Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jul 6, 2022

      Kyprolis® in Combination With Revlimid® and Dexamethasone or

      Recruiting
      • Multiple Myeloma in Relapse
      • Frankfurt, Germany
        Centrum für Hämatologie und Onkologie Bethanien
      Jun 2, 2022

      Multiple Myeloma Trial in Augusta (Lenalidomide, Vitamin D - Intensified, Vitamin D - Therapeutic)

      Not yet recruiting
      • Multiple Myeloma
      • Augusta, Georgia
        Georgia Cancer Center at Augusta University
      Apr 26, 2023

      Multiple Myeloma Trial (Dexamethasone, Isatuximab, Lenalidomide)

      Not yet recruiting
      • Multiple Myeloma
      • (no location specified)
      Jan 10, 2023

      High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma Trial in Boston (Teclistamab, Lenalidomide,

      Recruiting
      • High-risk Smoldering Multiple Myeloma
      • +2 more
      • Boston, Massachusetts
        Dana Farber Cancer Institute
      Aug 11, 2022

      B-cell Non-Hodgkin's Lymphoma Trial (IMM0306, Lenalidomide capsule)

      Not yet recruiting
      • B-cell Non-Hodgkin's Lymphoma
      • (no location specified)
      Mar 6, 2023

      Multiple Myeloma, Myeloma-Associated Amyloidosis Trial in Saint Louis (Selinexor, Lenalidomide, Dexamethasone)

      Not yet recruiting
      • Multiple Myeloma
      • Myeloma-Associated Amyloidosis
      • Saint Louis, Missouri
        Washington University School of Medicine
      Apr 6, 2023

      Myeloma, Multiple Myeloma Trial in Chicago (Daratumumab, Carfilzomib, Lenalidomide)

      Recruiting
      • Myeloma
      • Multiple Myeloma
      • Chicago, Illinois
        The University of Chicago
      Sep 15, 2021

      Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

      Not yet recruiting
      • Multiple Myeloma in Relapse
      • Multiple Myeloma, Refractory
      • (no location specified)
      Aug 8, 2022

      Lenalidomide in Combination With Dexamethasone in Clinical

      Active, not recruiting
      • Multiple Myeloma
        • Kirchdorf, Austria
        • +11 more
        May 16, 2022

        Lymphoma Trial in Houston (Rituximab, Lenalidomide, Valemetostat)

        Not yet recruiting
        • Lymphoma
        • Houston, Texas
          M D Anderson Cancer Center
        Jan 4, 2023